Ascentage Pharma's drug lisaftoclax just got special approval in China to help treat certain blood cancers.

Oct 20, 2026, 9:10 PM ETTrialRead the original at globenewswire.com

Good for AAPG

Ascentage Pharma’s lisaftoclax received China’s designation for first-line CLL/SLL use with acalabrutinib, which can speed development and review. Phase III trials are still underway, so this is progress, not an approval.

AAPG · Ascentage Pharma

AI read · Good for AAPG

The AI's read

A faster review path could help bring this use closer to patients, but the designation does not prove the treatment works or approve it for this group. Global Phase III trials continue. The existing China approval covers previously treated patients, not the first-line use in this announcement.

Get alerts for AAPG

Follow Ascentage Pharma (AAPG) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AAPG

Free on the App Store and Google Play, or on the web.